Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 4c; Cuts FY11 EPS Outlook
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.17, $0.04 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $40.05 million versus the consensus estimate of $43.13 million.
Meridian Bioscience, Inc. sees FY2011 EPS of $0.68-$0.71, versus prior guidance of $0.77-$0.82 and the consensus of $0.79.
Meridian Bioscience, Inc. sees FY2011 EPS of $0.68-$0.71, versus prior guidance of $0.77-$0.82 and the consensus of $0.79.